US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ARS PHARMACEUTICALS INC

14.44

+0.06000.42%

Volume:450.20K

Turnover:6.50M

Market Cap:1.42B

PE:180.50

High:14.73

Open:14.46

Low:14.20

Close:14.38

Loading ...

Overview Company News Filings

ARS Pharmaceuticals Announces Filings for Approval of Neffy® in China, Japan and Australia

THOMSON REUTERS

ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia

Stock Track | ARS Pharmaceuticals Soars 5.07% on neffyinSchools Program Launch for Needle-Free Epinephrine in Schools

ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost

Loss-Making ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Expected To Breakeven In The Medium-Term

Simply Wall St.

BRIEF-Neurelis Enters $208 Million Agreement To Monetize Intravail Royalties

Neurelis Enters $208 Million Agreement to Monetize Intravail Royalties

THOMSON REUTERS

ARS Pharmaceuticals Inc : Leerink Partners Raises Target Price to $26 From $25

THOMSON REUTERS

ARS Pharmaceuticals Inc (SPRY) Q3 2024 Earnings Call Highlights: Strong Cash Position and NEPHI ...

ARS Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary

BRIEF-ARS Pharmaceuticals Reports Q3 2024 Financial Results And Provides Business Updates

ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates

ARS Pharmaceuticals Q3 2024 GAAP EPS $(0.20) Misses $(0.14) Estimate, Sales $2.068M Beat $565.000K Estimate. Cash and Equivalents Of $349.6M

ARS Pharmaceuticals Q3 Operating Income USD -21.748 Million

THOMSON REUTERS

ARS Pharmaceuticals Q3 Revenue USD 568 Thousand VS. Ibes Estimate USD 575 Thousand

THOMSON REUTERS

ARS Pharmaceuticals: Pdufa Target Date Set for March 6, 2025

THOMSON REUTERS

ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

THOMSON REUTERS

ARS Pharmaceuticals: Cash, Cash Equivalents and Short-Term Investments Were $204.6 Mln as of September 30, 2024

THOMSON REUTERS

Press Release: ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

ARS Pharmaceuticals Inc expected to post a loss of 15 cents a share - Earnings Preview

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/SPRY/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SPRY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SPRY\",,,,,undefined,":{"symbol":"SPRY","market":"US","secType":"STK","nameCN":"ARS PHARMACEUTICALS INC","latestPrice":14.44,"timestamp":1745523618381,"preClose":14.38,"halted":0,"volume":450197,"delay":0,"floatShares":47453121,"shares":98119804,"eps":0.079999,"marketStatus":"Trading","change":0.06,"latestTime":"04-24 15:40:18 EDT","open":14.46,"high":14.73,"low":14.2,"amount":6498841.30335,"amplitude":0.036857,"askPrice":14.45,"askSize":122,"bidPrice":14.43,"bidSize":221,"shortable":3,"etf":0,"ttmEps":0.079999,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745524800000},"marketStatusCode":2,"adr":0,"listingDate":1607058000000,"exchange":"NASDAQ","adjPreClose":14.38,"preHourTrading":{"tag":"盘前","latestPrice":14.38,"preClose":14.38,"latestTime":"08:16 EDT","volume":605,"amount":9218.68024,"timestamp":1745496969560},"postHourTrading":{"tag":"盘后","latestPrice":14.53,"preClose":14.38,"latestTime":"19:48 EDT","volume":12179,"amount":175271.83,"timestamp":1745452088274},"volumeRatio":0.289255,"impliedVol":0.8239,"impliedVolPercentile":0.628},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SPRY\",,,,,undefined,":{"symbol":"SPRY","floatShares":47453121,"roa":"-0.66%","roe":"3.28%","lyrEps":0.082507,"volumeRatio":0.289255,"shares":98119804,"dividePrice":0,"high":14.73,"amplitude":0.036857,"preClose":14.38,"low":14.2,"week52Low":7.55,"pbRate":"5.52","psRate":"15.89","week52High":18.51,"institutionHeld":0,"latestPrice":14.44,"committee":0.28863,"eps":0.079999,"divideRate":0,"volume":450197,"delay":0,"ttmEps":0.079999,"open":14.46,"prevYearClose":10.55,"prevWeekClose":14.88,"prevMonthClose":12.58,"prevQuarterClose":12.58,"fiveDayClose":14.88,"twentyDayClose":12.6,"sixtyDayClose":14.88},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SPRY\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2491435573","title":"ARS Pharmaceuticals Announces Filings for Approval of Neffy® in China, Japan and Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2491435573","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491435573?lang=en_us&edition=fundamental","pubTime":"2024-12-13 03:32","pubTimestamp":1734031962,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241212:nFWN3ND1MO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2491356690","title":"ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2491356690","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491356690?lang=en_us&edition=fundamental","pubTime":"2024-12-13 03:32","pubTimestamp":1734031920,"startTime":"0","endTime":"0","summary":"Licensing partners in key Asia Pacific countries have filed for approval of neffy  2 mg with regulatory agencies. “Given the life-saving potential of neffy for the emergency treatment of severe allergic reactions, our focus is on making it available as quickly and as broadly as possible worldwide,” says Richard Lowenthal, Co-Founder, President and CEO of ARS Pharmaceuticals. “People in the Asia Pacific region could soon be saying hello to neffy where the unique attributes of the product, such as being needle-free, easy to dispose, a smaller size with temperature excursions up to 122°F , and a 30 month shelf life are particularly important. We are thankful to our licensing partners in these countries for filing with their respective regulatory agencies.”ARS Pharma retains all U.S. rights for neffy and has existing licensing partnerships in China, Japan, Australia and New Zealand with Pediatrix Therapeutics, Alfresa Pharma, and CSL Seqirus, respectively. ARS Pharma also has an exclusive ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/2662Y2FQHMfQLid_BOesTg--~B/aD0zMTE7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/58ce048b192bf8bfd3f62881dd68376c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/2662Y2FQHMfQLid_BOesTg--~B/aD0zMTE7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/58ce048b192bf8bfd3f62881dd68376c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ars-pharmaceuticals-announces-filings-approval-193200902.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"1124471356","title":"Stock Track | ARS Pharmaceuticals Soars 5.07% on neffyinSchools Program Launch for Needle-Free Epinephrine in Schools","url":"https://stock-news.laohu8.com/highlight/detail?id=1124471356","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124471356?lang=en_us&edition=fundamental","pubTime":"2024-12-05 04:42","pubTimestamp":1733344944,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc  saw its stock soar 5.07% in Wednesday's intraday trading session, outperforming the broader market. This surge comes after the company announced the planned launch of its \"neffyinSchools\" program in January 2025.The neffyinSchools program aims to provide eligible public and private K-12 schools in the U.S. with free doses of neffy, ARS Pharmaceuticals' recently approved needle-free epinephrine nasal spray for emergency treatment of Type I allergic reactions, including an","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | ARS Pharmaceuticals Soars 5.07% on neffyinSchools Program Launch for Needle-Free Epinephrine in Schools","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SPRY"],"gpt_icon":0},{"id":"2488195200","title":"ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost","url":"https://stock-news.laohu8.com/highlight/detail?id=2488195200","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488195200?lang=en_us&edition=fundamental","pubTime":"2024-12-04 21:00","pubTimestamp":1733317200,"startTime":"0","endTime":"0","summary":"Qualifying public and private K-12 Schools in the U.S. will be eligible to receive two free cartons  of neffy  2mg for use in emergency treatment of allergic reactions including anaphylaxis. Interested schools are encouraged to review applicable state laws and regulations to ensure neffy for undesignated use meets all requirements. Type 1 allergic reactions can be life-threatening, can happen in minutes, andcan be caused by stinging and biting insects, foods, medication, exercise, or other unknown causes. Studies show that up to 18% of children with food allergies have had a reaction from accidentally eating food allergens while at school.1 In addition, 25% of severe and potentially life-threatening reactions  reported at schools happened in children with no previous diagnosis of food allergy.1. In advance of the neffyinSchools launch, schools are encouraged to review applicable state legislation to ensure neffy meets the requirements of local epinephrine stocking and indemnification l","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/2662Y2FQHMfQLid_BOesTg--~B/aD0zMTE7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/58ce048b192bf8bfd3f62881dd68376c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/2662Y2FQHMfQLid_BOesTg--~B/aD0zMTE7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/58ce048b192bf8bfd3f62881dd68376c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ars-pharmaceuticals-announces-planned-launch-130000071.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2483327760","title":"Loss-Making ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Expected To Breakeven In The Medium-Term","url":"https://stock-news.laohu8.com/highlight/detail?id=2483327760","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483327760?lang=en_us&edition=fundamental","pubTime":"2024-11-15 19:50","pubTimestamp":1731671422,"startTime":"0","endTime":"0","summary":"With the business potentially at an important milestone, we thought we'd take a closer look at ARS Pharmaceuticals, Inc.'s  future prospects. ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. With the latest financial year loss of US$54m and a trailing-twelve-month loss of US$49m, the US$1.4b market-cap company alleviated its loss by moving closer towards its target of breakeven. Many investors are wondering about the rate at which ARS Pharmaceuticals will turn a profit, with the big question being “when will the company breakeven?”In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.Working backwards from analyst estimates, it turns out that they expect the company to grow 57% year-on-year, on average, which is extremely buoyant. Should the business grow at a slower rate, it will become profitable at a later date than expected.Management Team: An experienced","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/loss-making-ars-pharmaceuticals-inc-115022646.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NQmain","BK4139","IE00BKPKM429.USD","NDAQ","MNQmain",".IXIC","IE00B64PRP62.GBP","LU2210149790.SGD","BK4112","IE00B3QW5Z07.USD","QLD","SPRY","IE00BGHQF748.EUR","PSQ","LU2210150020.SGD","LU2095319765.USD","QID","SQQQ","BK4585","BK4588","TQQQ"],"gpt_icon":1},{"id":"2483063308","title":"BRIEF-Neurelis Enters $208 Million Agreement To Monetize Intravail Royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2483063308","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483063308?lang=en_us&edition=fundamental","pubTime":"2024-11-14 22:02","pubTimestamp":1731592960,"startTime":"0","endTime":"0","summary":"Nov 14 (Reuters) - ARS Pharmaceuticals Inc   :   * NEURELIS ENTERS $208 MILLION AGREEMENT TO MONETIZE INTRAVAIL ROYALTIESSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2483805202","title":"Neurelis Enters $208 Million Agreement to Monetize Intravail Royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2483805202","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483805202?lang=en_us&edition=fundamental","pubTime":"2024-11-14 22:00","pubTimestamp":1731592824,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nTUABPYMYH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2483939849","title":"ARS Pharmaceuticals Inc :  Leerink Partners Raises Target Price to $26 From $25","url":"https://stock-news.laohu8.com/highlight/detail?id=2483939849","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483939849?lang=en_us&edition=fundamental","pubTime":"2024-11-14 15:58","pubTimestamp":1731571130,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nFWN3ML095:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2483384844","title":"ARS Pharmaceuticals Inc (SPRY) Q3 2024 Earnings Call Highlights: Strong Cash Position and NEPHI ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2483384844","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483384844?lang=en_us&edition=fundamental","pubTime":"2024-11-14 15:08","pubTimestamp":1731568081,"startTime":"0","endTime":"0","summary":"Net Product Revenue for NEPI: $0.6 million from one week of sales.Total Operating Expenses: $23.8 million in Q3 2024.SG&A Expenses: $19.3 million, expected to increase in Q4 2024.GAAP Net Loss: $19.1 million or $0.20 per share in Q3 2024.Cash, Cash Equivalents, and Short-term Investments: $204.6 million at the end of Q3 2024.Pro Forma Cash Position: $349.6 million including $145 million upfront payment from ALK.GuruFocus has detected 3 Warning Sign with SPRY.For the complete transcript of the earnings call, please refer to the full earnings call transcript.The company has launched NEPHI in the U.S., with strong support and enthusiasm from patients, caregivers, and the medical community.A strategic licensing agreement with AOK has been established, expanding NEPHI's reach to Europe, Canada, and other regions.ARS Pharmaceuticals Inc  has a strong cash position of approximately $350 million, supporting its launch efforts and global expansion.The company is actively engaging with key payer","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ars-pharmaceuticals-inc-spry-q3-070801605.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SPRY"],"gpt_icon":1},{"id":"2483288630","title":"ARS Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2483288630","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483288630?lang=en_us&edition=fundamental","pubTime":"2024-11-13 22:17","pubTimestamp":1731507463,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings SummaryARS Pharmaceuticals Inc SPRY.OQ reported a quarterly adjusted loss of 20 cents per share for the quarter en","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nL8N3MK1JR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY"],"gpt_icon":0},{"id":"2483040220","title":"BRIEF-ARS Pharmaceuticals Reports Q3 2024 Financial Results And Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2483040220","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483040220?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:56","pubTimestamp":1731502613,"startTime":"0","endTime":"0","summary":"Nov 13  - ARS Pharmaceuticals Inc   :   * ARS PHARMACEUTICALS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES   * ARS PHARMACEUTICALS: PDUFA TARGET DATE SET FOR MARCH 6, 2025   * ARS PHARMACEUTICALS: CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS WERE $204.6 MILLION AS OF SEPTEMBER 30, 2024Source text:   Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2483884939","title":"ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2483884939","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483884939?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:40","pubTimestamp":1731501604,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals, Inc.  came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.16 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -11.11%. A quarter ago, it was expected that this company would post a loss of $0.12 per share when it actually produced a loss of $0.13, delivering a surprise of -8.33%.ARS Pharmaceuticals, Inc. , which belongs to the Zacks Medical - Drugs industry, posted revenues of $2.07 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 8.50%. This compares to zero revenues a year ago.While ARS Pharmaceuticals, Inc. Has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ZVGBNd2_.kAicju5mLde7g--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/71afbbc0512eb3c471136d93f39079c9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ZVGBNd2_.kAicju5mLde7g--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/71afbbc0512eb3c471136d93f39079c9"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ars-pharmaceuticals-inc-spry-reports-124004917.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SPRY"],"gpt_icon":0},{"id":"2483008128","title":"ARS Pharmaceuticals Q3 2024 GAAP EPS $(0.20) Misses $(0.14) Estimate, Sales $2.068M Beat $565.000K Estimate. Cash and Equivalents Of $349.6M","url":"https://stock-news.laohu8.com/highlight/detail?id=2483008128","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483008128?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:32","pubTimestamp":1731497559,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.14) by 42.86 percent. This is a 25 percent decrease over losses of $(0.16) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41934221/ars-pharmaceuticals-q3-2024-gaap-eps-0-20-misses-0-14-estimate-sales-2-068m-beat-565-000k-estimate-","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"ARS Pharmaceuticals Q3 2024 GAAP EPS $(0.20) Misses $(0.14) Estimate, Sales $2.068M Beat $565.000K Estimate. Cash and Equivalents Of $349.6M","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY"],"gpt_icon":0},{"id":"2483086850","title":"ARS Pharmaceuticals Q3 Operating Income USD -21.748 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2483086850","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483086850?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:30","pubTimestamp":1731497401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nPLX69CC25:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2483600893","title":"ARS Pharmaceuticals Q3 Revenue USD 568 Thousand VS. Ibes Estimate USD 575 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2483600893","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483600893?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:30","pubTimestamp":1731497401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nPLX69CC25:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2483008956","title":"ARS Pharmaceuticals: Pdufa Target Date Set for March 6, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2483008956","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483008956?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:30","pubTimestamp":1731497401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUA6CJXCL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2483008509","title":"ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2483008509","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483008509?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:30","pubTimestamp":1731497401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUA6CJXCL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2483008157","title":"ARS Pharmaceuticals: Cash, Cash Equivalents and Short-Term Investments Were $204.6 Mln as of September 30, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483008157","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483008157?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:30","pubTimestamp":1731497401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUA6CJXCL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2483008267","title":"Press Release: ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2483008267","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483008267?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:30","pubTimestamp":1731497400,"startTime":"0","endTime":"0","summary":"Commercial launch of neffy  underway in the United States. Supplemental NDA for neffy 1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025. Exclusive license agreement with ALK-Abelló to commercialize neffy in Europe, Canada and certain other geographies; ARS Pharma to receive $145 million in upfront payment with total deal consideration of up to $465 million plus double-digit royalties. Well-capitalized with $349.6 million in cash, cash equivalents and short-term investments on a pro forma basis, supporting an operating runway of at least three years. On August 9, 2024, the FDA approved neffy  2 mg for the treatment of Type 1 allergic reactions, including anaphylaxis, in adults and children who weigh >=30 kg . neffy was first available for shipment on September 23, 2024, and in early October, the U.S. sales force started in the field and neffy became broadly available in retail pharmacies.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4022","R","SPRY","BK4232"],"gpt_icon":0},{"id":"2482635739","title":"ARS Pharmaceuticals Inc    expected to post a loss of 15 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2482635739","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482635739?lang=en_us&edition=fundamental","pubTime":"2024-11-11 23:34","pubTimestamp":1731339269,"startTime":"0","endTime":"0","summary":"* ARS Pharmaceuticals Inc     is expected to show a rise in quarterly revenue when it reports  results on November 13 for the period ending September 30 2024   * The San Diego California-based  compan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"ARS Pharmaceuticals Inc    expected to post a loss of 15 cents a share - Earnings Preview","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":5,"totalSize":111,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SPRY\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-20","symbol":"SPRY","fiscalQuarterEnding":"2024/12","expectedEps":-0.04,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1742443200000,"reportTimeType":"pre","actualEps":0.52},{"market":"US","date":"2025-01-13","symbol":"SPRY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1736744400000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2024-11-13","symbol":"SPRY","fiscalQuarterEnding":"2024/09","expectedEps":-0.18,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"pre","actualEps":-0.2},{"market":"US","date":"2024-08-06","symbol":"SPRY","fiscalQuarterEnding":"2024/06","expectedEps":-0.12,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1722916800000,"reportTimeType":"post","actualEps":-0.13},{"market":"US","date":"2024-05-09","symbol":"SPRY","fiscalQuarterEnding":"2024/03","expectedEps":-0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"post","actualEps":-0.11}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SPRY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SPRY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.3333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":6,"updateTime":1741320000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SPRY\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SPRY","date":"2025-04-23","current":184.020638,"percent":1,"low":-41.829007,"twenty":-28.563473,"median":-17.701176,"eighty":-11.836649,"high":184.020638,"avg":-12.79323,"sd":37.321686,"marketCap":1471797060},"quantilePoints":[{"date":"2022-11-11","current":-28.534516,"twenty":-28.349227,"median":-28.071294,"eighty":-27.904534,"marketCap":577624216},{"date":"2022-11-18","current":-27.515427,"twenty":-28.349227,"median":-28.00181,"eighty":-27.867476,"marketCap":556994780},{"date":"2022-11-25","current":-28.627161,"twenty":-29.164499,"median":-28.302905,"eighty":-27.978649,"marketCap":579499619},{"date":"2022-12-02","current":-32.332942,"twenty":-29.813011,"median":-28.534516,"eighty":-27.978649,"marketCap":654515751},{"date":"2022-12-09","current":-33.352032,"twenty":-32.629404,"median":-28.951417,"eighty":-27.987913,"marketCap":675145188},{"date":"2022-12-16","current":-37.428392,"twenty":-33.870842,"median":-29.970507,"eighty":-28.034236,"marketCap":757662933},{"date":"2022-12-23","current":-37.428392,"twenty":-36.761351,"median":-31.221208,"eighty":-28.136145,"marketCap":757662933},{"date":"2022-12-30","current":-39.512894,"twenty":-37.428392,"median":-32.842487,"eighty":-28.39555,"marketCap":799859507},{"date":"2023-01-06","current":-33.490999,"twenty":-37.558094,"median":-33.236227,"eighty":-28.506723,"marketCap":677958292},{"date":"2023-01-13","current":-34.510089,"twenty":-37.428392,"median":-33.352032,"eighty":-28.608632,"marketCap":698587729},{"date":"2023-01-20","current":-24.704541,"twenty":-37.261632,"median":-32.981454,"eighty":-28.089644,"marketCap":627322403},{"date":"2023-01-27","current":-23.338221,"twenty":-36.955904,"median":-32.518231,"eighty":-27.978649,"marketCap":592627442},{"date":"2023-02-03","current":-26.292426,"twenty":-36.631648,"median":-30.109473,"eighty":-26.233342,"marketCap":667643574},{"date":"2023-02-10","current":-28.323442,"twenty":-36.44636,"median":-29.576768,"eighty":-26.233342,"marketCap":719217165},{"date":"2023-02-17","current":-31.868488,"twenty":-36.103575,"median":-29.970507,"eighty":-27.026227,"marketCap":809236523},{"date":"2023-02-24","current":-30.539096,"twenty":-35.51065,"median":-30.109473,"eighty":-27.543213,"marketCap":775479264},{"date":"2023-03-03","current":-33.641011,"twenty":-34.760229,"median":-30.612951,"eighty":-27.668279,"marketCap":854246203},{"date":"2023-03-10","current":-29.025066,"twenty":-34.306271,"median":-30.649879,"eighty":-27.867476,"marketCap":737033496},{"date":"2023-03-17","current":-31.056082,"twenty":-33.963486,"median":-30.631415,"eighty":-27.978649,"marketCap":788607087},{"date":"2023-03-24","current":-20.659679,"twenty":-33.801144,"median":-30.612951,"eighty":-27.867476,"marketCap":716518982},{"date":"2023-03-31","current":-17.719962,"twenty":-33.618064,"median":-30.576023,"eighty":-26.2038,"marketCap":614563712},{"date":"2023-04-06","current":-15.732931,"twenty":-33.565575,"median":-30.176574,"eighty":-25.70897,"marketCap":545649501},{"date":"2023-04-14","current":-16.631178,"twenty":-33.492841,"median":-29.970507,"eighty":-24.113699,"marketCap":576802501},{"date":"2023-04-21","current":-17.973502,"twenty":-33.463206,"median":-29.344076,"eighty":-23.419462,"marketCap":623356984},{"date":"2023-04-28","current":-17.210989,"twenty":-33.352032,"median":-29.090384,"eighty":-19.070054,"marketCap":596911536},{"date":"2023-05-05","current":-16.693286,"twenty":-33.350744,"median":-28.918758,"eighty":-18.073817,"marketCap":578956528},{"date":"2023-05-12","current":-12.329028,"twenty":-33.323434,"median":-28.627161,"eighty":-17.841072,"marketCap":427595344},{"date":"2023-05-19","current":-17.294264,"twenty":-33.212652,"median":-28.359496,"eighty":-17.789501,"marketCap":733155735},{"date":"2023-05-26","current":-17.057707,"twenty":-33.123305,"median":-28.101877,"eighty":-17.789501,"marketCap":723127390},{"date":"2023-06-02","current":-15.358643,"twenty":-33.120421,"median":-28.024971,"eighty":-17.719962,"marketCap":651098973},{"date":"2023-06-09","current":-15.179795,"twenty":-32.981454,"median":-27.978649,"eighty":-17.665522,"marketCap":643517035},{"date":"2023-06-16","current":-13.525443,"twenty":-32.939388,"median":-27.584891,"eighty":-17.230009,"marketCap":573384103},{"date":"2023-06-23","current":-14.352619,"twenty":-32.898926,"median":-26.292426,"eighty":-16.984823,"marketCap":608450569},{"date":"2023-06-30","current":-14.777385,"twenty":-32.852687,"median":-26.033933,"eighty":-16.443167,"marketCap":626457673},{"date":"2023-07-07","current":-14.374975,"twenty":-32.778571,"median":-25.664657,"eighty":-16.200645,"marketCap":609398311},{"date":"2023-07-14","current":-15.381,"twenty":-32.650157,"median":-24.815323,"eighty":-15.896248,"marketCap":652046716},{"date":"2023-07-20","current":-16.342312,"twenty":-32.522678,"median":-23.947525,"eighty":-15.738555,"marketCap":692799635},{"date":"2023-07-28","current":-14.889165,"twenty":-32.268091,"median":-23.449004,"eighty":-15.666005,"marketCap":631196385},{"date":"2023-08-04","current":-15.649273,"twenty":-31.980646,"median":-22.434463,"eighty":-15.664922,"marketCap":663419624},{"date":"2023-08-11","current":-12.27233,"twenty":-31.772476,"median":-20.321699,"eighty":-15.577733,"marketCap":654642902},{"date":"2023-08-18","current":-12.05734,"twenty":-31.358888,"median":-18.902086,"eighty":-15.443597,"marketCap":643174706},{"date":"2023-08-25","current":-12.361909,"twenty":-31.218563,"median":-18.499284,"eighty":-15.287104,"marketCap":659421318},{"date":"2023-08-30","current":-12.70231,"twenty":-31.152094,"median":-18.359623,"eighty":-15.152968,"marketCap":677579296},{"date":"2023-09-08","current":-13.114373,"twenty":-31.100395,"median":-18.231502,"eighty":-15.005417,"marketCap":699560007},{"date":"2023-09-15","current":-13.04271,"twenty":-31.033926,"median":-18.031385,"eighty":-14.777385,"marketCap":695737274},{"date":"2023-09-20","current":-11.833393,"twenty":-31.022847,"median":-18.002563,"eighty":-14.750557,"marketCap":631228667},{"date":"2023-09-27","current":-6.718429,"twenty":-31.011769,"median":-17.988032,"eighty":-14.670075,"marketCap":358381151},{"date":"2023-10-05","current":-7.166324,"twenty":-30.867751,"median":-17.964938,"eighty":-14.419687,"marketCap":382273228},{"date":"2023-10-13","current":-6.718429,"twenty":-30.668342,"median":-17.875755,"eighty":-14.196126,"marketCap":358381151},{"date":"2023-10-20","current":-6.055544,"twenty":-30.649879,"median":-17.782874,"eighty":-14.047454,"marketCap":323020877},{"date":"2023-10-27","current":-6.306365,"twenty":-30.649879,"median":-17.728408,"eighty":-14.012806,"marketCap":336400440},{"date":"2023-11-03","current":-6.539271,"twenty":-30.635108,"median":-17.710569,"eighty":-13.713234,"marketCap":348824320},{"date":"2023-11-10","current":-5.319172,"twenty":-30.612951,"median":-17.665522,"eighty":-13.225451,"marketCap":327799293},{"date":"2023-11-17","current":-7.025405,"twenty":-30.612951,"median":-17.36121,"eighty":-12.859969,"marketCap":432947606},{"date":"2023-11-24","current":-7.41484,"twenty":-30.59818,"median":-17.220775,"eighty":-12.627063,"marketCap":456946919},{"date":"2023-12-01","current":-7.523882,"twenty":-30.480012,"median":-17.057707,"eighty":-12.494486,"marketCap":463666727},{"date":"2023-12-08","current":-8.1314,"twenty":-30.216835,"median":-16.553813,"eighty":-12.335604,"marketCap":501105655},{"date":"2023-12-15","current":-8.115823,"twenty":-30.090944,"median":-16.431736,"eighty":-12.243664,"marketCap":500145682},{"date":"2023-12-22","current":-7.944471,"twenty":-30.007565,"median":-16.309818,"eighty":-8.996418,"marketCap":489585985},{"date":"2023-12-29","current":-8.770073,"twenty":-29.979771,"median":-16.222884,"eighty":-8.287174,"marketCap":540464528},{"date":"2024-01-05","current":-8.785651,"twenty":-29.917293,"median":-16.174641,"eighty":-8.399331,"marketCap":541424501},{"date":"2024-01-12","current":-9.112776,"twenty":-29.704533,"median":-16.005127,"eighty":-8.58626,"marketCap":561583924},{"date":"2024-01-19","current":-9.471056,"twenty":-29.440705,"median":-15.977907,"eighty":-8.629876,"marketCap":583663292},{"date":"2024-01-26","current":-10.156461,"twenty":-29.180978,"median":-15.857321,"eighty":-8.707763,"marketCap":625902083},{"date":"2024-02-02","current":-9.969533,"twenty":-29.156298,"median":-15.732931,"eighty":-8.773189,"marketCap":614382412},{"date":"2024-02-09","current":-10.109729,"twenty":-29.07732,"median":-15.682807,"eighty":-8.798113,"marketCap":623022165},{"date":"2024-02-16","current":-11.309188,"twenty":-29.025066,"median":-15.649273,"eighty":-8.900923,"marketCap":696940049},{"date":"2024-02-23","current":-11.83882,"twenty":-29.025066,"median":-15.515136,"eighty":-9.112776,"marketCap":729579115},{"date":"2024-03-01","current":-13.038279,"twenty":-28.81245,"median":-15.453657,"eighty":-9.20624,"marketCap":803496999},{"date":"2024-03-08","current":-13.941768,"twenty":-28.8035,"median":-15.381,"eighty":-9.20624,"marketCap":859175405},{"date":"2024-03-15","current":-14.019655,"twenty":-28.627161,"median":-15.258041,"eighty":-9.237395,"marketCap":863975268},{"date":"2024-03-22","current":-15.975609,"twenty":-28.534516,"median":-15.179795,"eighty":-9.252972,"marketCap":868513986},{"date":"2024-03-28","current":-17.679674,"twenty":-28.423343,"median":-15.269219,"eighty":-9.315282,"marketCap":961155477},{"date":"2024-04-05","current":-16.916395,"twenty":-28.337864,"median":-15.369822,"eighty":-9.405631,"marketCap":919659809},{"date":"2024-04-12","current":-16.401625,"twenty":-28.264358,"median":-15.43689,"eighty":-9.46171,"marketCap":891674358},{"date":"2024-04-19","current":-14.981571,"twenty":-28.131419,"median":-15.49278,"eighty":-9.483518,"marketCap":814473115},{"date":"2024-04-26","current":-14.360297,"twenty":-28.077411,"median":-15.403356,"eighty":-9.636176,"marketCap":780697571},{"date":"2024-05-03","current":-16.860498,"twenty":-28.034236,"median":-15.420123,"eighty":-9.72341,"marketCap":916620967},{"date":"2024-05-10","current":-17.157732,"twenty":-27.987913,"median":-15.505955,"eighty":-9.779488,"marketCap":852670667},{"date":"2024-05-17","current":-17.742813,"twenty":-27.978649,"median":-15.537492,"eighty":-9.809086,"marketCap":881746829},{"date":"2024-05-24","current":-17.157885,"twenty":-27.978649,"median":-15.649273,"eighty":-9.876069,"marketCap":852678252},{"date":"2024-05-31","current":-17.372359,"twenty":-27.867476,"median":-15.716341,"eighty":-9.910338,"marketCap":863336730},{"date":"2024-06-07","current":-17.19688,"twenty":-27.668279,"median":-15.746992,"eighty":-9.932147,"marketCap":854616157},{"date":"2024-06-14","current":-17.430851,"twenty":-27.557105,"median":-15.857321,"eighty":-9.95084,"marketCap":866243588},{"date":"2024-06-21","current":-15.071642,"twenty":-27.270827,"median":-15.857321,"eighty":-9.975764,"marketCap":749000328},{"date":"2024-06-28","current":-15.695565,"twenty":-26.781626,"median":-15.857321,"eighty":-9.988225,"marketCap":780006810},{"date":"2024-07-05","current":-17.723315,"twenty":-26.233342,"median":-15.924221,"eighty":-10.038073,"marketCap":880777877},{"date":"2024-07-12","current":-21.66183,"twenty":-26.100403,"median":-16.005127,"eighty":-10.100383,"marketCap":1076506294},{"date":"2024-07-15","current":-22.129772,"twenty":-26.078246,"median":-16.005127,"eighty":-10.103498,"marketCap":1099761155},{"date":"2024-08-02","current":-20.452979,"twenty":-26.05609,"median":-16.005127,"eighty":-10.106614,"marketCap":1016431235},{"date":"2024-08-09","current":-21.380681,"twenty":-25.915765,"median":-16.072487,"eighty":-10.122191,"marketCap":958752513},{"date":"2024-08-16","current":-29.271428,"twenty":-26.174258,"median":-16.163463,"eighty":-10.15023,"marketCap":1312589385},{"date":"2024-08-23","current":-27.693279,"twenty":-27.713295,"median":-16.214626,"eighty":-10.468009,"marketCap":1241822011},{"date":"2024-08-30","current":-28.060793,"twenty":-27.98643,"median":-16.295121,"eighty":-10.844982,"marketCap":1258302084},{"date":"2024-09-06","current":-25.401719,"twenty":-27.994212,"median":-16.393243,"eighty":-10.985179,"marketCap":1139063905},{"date":"2024-09-13","current":-27.304146,"twenty":-27.978649,"median":-16.401625,"eighty":-11.047488,"marketCap":1224372521},{"date":"2024-09-20","current":-32.125068,"twenty":-28.0393,"median":-16.454093,"eighty":-11.125375,"marketCap":1440552309},{"date":"2024-09-27","current":-31.368421,"twenty":-28.102738,"median":-16.474539,"eighty":-11.25311,"marketCap":1406622746},{"date":"2024-10-04","current":-30.265879,"twenty":-28.279129,"median":-16.592455,"eighty":-11.496117,"marketCap":1357182526},{"date":"2024-10-11","current":-30.071312,"twenty":-28.572704,"median":-16.658407,"eighty":-11.620736,"marketCap":1348457781},{"date":"2024-10-18","current":-34.870616,"twenty":-28.814446,"median":-16.809891,"eighty":-11.676815,"marketCap":1563668153},{"date":"2024-10-25","current":-33.292466,"twenty":-29.051193,"median":-16.869409,"eighty":-11.785716,"marketCap":1492900778},{"date":"2024-10-31","current":-30.849578,"twenty":-29.236068,"median":-16.900657,"eighty":-11.835564,"marketCap":1383356760},{"date":"2024-11-08","current":-34.892234,"twenty":-29.613,"median":-17.040899,"eighty":-11.890396,"marketCap":1564637569},{"date":"2024-11-15","current":-27.926178,"twenty":-29.784002,"median":-17.157809,"eighty":-12.003593,"marketCap":1371287052},{"date":"2024-11-22","current":-26.481379,"twenty":-29.677856,"median":-17.19688,"eighty":-12.129003,"marketCap":1300341655},{"date":"2024-11-29","current":-28.717849,"twenty":-29.625971,"median":-17.210989,"eighty":-12.243664,"marketCap":1410161242},{"date":"2024-12-06","current":-27.708469,"twenty":-29.56544,"median":-17.223194,"eighty":-12.275913,"marketCap":1360596650},{"date":"2024-12-13","current":-25.016789,"twenty":-29.525705,"median":-17.313866,"eighty":-12.298002,"marketCap":1228424404},{"date":"2024-12-20","current":-22.404276,"twenty":-29.458385,"median":-17.352861,"eighty":-12.329028,"marketCap":1100139577},{"date":"2024-12-27","current":-22.067816,"twenty":-29.271428,"median":-17.394358,"eighty":-12.329028,"marketCap":1083618046},{"date":"2025-01-03","current":-21.196979,"twenty":-29.200708,"median":-17.429503,"eighty":-12.355333,"marketCap":1040856437},{"date":"2025-01-10","current":-22.621986,"twenty":-29.176877,"median":-17.469847,"eighty":-12.383408,"marketCap":1110829979},{"date":"2025-01-17","current":-24.106368,"twenty":-29.123341,"median":-17.508842,"eighty":-12.41924,"marketCap":1183719085},{"date":"2025-01-24","current":-27.490759,"twenty":-29.064257,"median":-17.592246,"eighty":-12.455071,"marketCap":1349906247},{"date":"2025-01-31","current":-28.28243,"twenty":-29.064257,"median":-17.626125,"eighty":-12.501652,"marketCap":1388780437},{"date":"2025-02-07","current":-25.333457,"twenty":-29.025066,"median":-17.679674,"eighty":-12.537484,"marketCap":1243974080},{"date":"2025-02-14","current":-23.591782,"twenty":-29.002547,"median":-17.701176,"eighty":-12.573316,"marketCap":1158450862},{"date":"2025-02-21","current":-23.314697,"twenty":-28.938503,"median":-17.719962,"eighty":-12.598398,"marketCap":1144844895},{"date":"2025-02-28","current":-20.187599,"twenty":-28.816442,"median":-17.723315,"eighty":-12.627063,"marketCap":991291845},{"date":"2025-03-07","current":-21.355313,"twenty":-28.81066,"median":-17.742813,"eighty":-12.687977,"marketCap":1048631275},{"date":"2025-03-14","current":-23.651157,"twenty":-28.793317,"median":-17.742813,"eighty":-12.709476,"marketCap":1161366426},{"date":"2025-03-21","current":175.555688,"twenty":-28.745638,"median":-17.756493,"eighty":-12.709476,"marketCap":1404094395},{"date":"2025-03-28","current":154.945377,"twenty":-28.717849,"median":-17.742813,"eighty":-12.566149,"marketCap":1239253124},{"date":"2025-04-04","current":164.39177,"twenty":-28.699711,"median":-17.73561,"eighty":-12.404907,"marketCap":1314805373},{"date":"2025-04-11","current":162.428883,"twenty":-28.621548,"median":-17.723315,"eighty":-12.298002,"marketCap":1299106204},{"date":"2025-04-17","current":182.548472,"twenty":-28.599098,"median":-17.719962,"eighty":-12.05734,"marketCap":1460022683},{"date":"2025-04-23","current":184.020638,"twenty":-28.563473,"median":-17.701176,"eighty":-11.836649,"marketCap":1471797060}],"updateTime":1745490621473}}}